-
12 April 2012 - Dexia Securities France releases a study on Neovacs (French only) :
Target price: 8,00 €
More :
-
15 March 2012 - The French Arthritis Foundation praises research by Neovacs :
More :
-
24 February 2012 - Following the publication of annual results, Edison Investment Research publishes a note on Neovacs :
More :
-
23 February 2012 - Alpha Value confirms its increased target price for Neovacs :
New target price : 7,40 €
More :
-
20 February 2012 - Neovacs publishes its 2011 annual results :
2011 Financial results in line with expectations
More :
-
25 January 2012 - Alpha Value has increased target price for Neovacs :
price target:7,35€
More :
-
05 January 2012 - The Phase IIa study in rheumatoid arthritis meets its endpoint :
The trial constitutes further confirmation of the Kinoids’ potential as active immunotherapies
More :
-
15 December 2011 - completion of patient recruitment in its phase II trial in Crohn's disease :
More :
-
08 November 2011 - Success for the phase I/II study in lupus :
Final results show excellent tolerability, strong immunogenicity and a significant activity on lupus biomarkers.
More :
-
08 November 2011 - The ACR published press release :
More :
-
26 October 2011 - Publication of promising initial results in the Phase IIa study in Rheumatoid Arthritis :
The initial results in the TNF-K-003 Phase IIa clinical trial in rheumatoid arthritis are promissing.
More :
-
27 September 2011 - First Half Financial Results 2011 :
Neovacs reports First Half 2011 Financial Results
More :
-
25 August 2011 - 2011 ACR/ARHP Scientific Meeting: IFNα-Kinoid selected for an oral presentation :
Neovacs today announced that its phase I/II results with IFNα-Kinoid in lupus patients will be the subject of an oral presentation at the 2011 American College of Rheumatology and Association of Rheumatology Health Professionals Meeting. The ACR/ARHP Meeting is the world largest gathering of physicians and researchers in the field of rheumatologic diseases.
The presentation is scheduled for November 8th 2011.
More :
-
03 August 2011 - Recruitment of all patients for Phase IIa clinical study of TNF-Kinoid in rheumatoid arthritis :
Neovacs has announced today that its TNF-K-003 clinical study has recruited all patients called for by the study protocol and consistent with the Company’s development plan. Initial results should be announced during the fall and final results by the end of 2011.
More :
-
26 July 2011 - Phase I/II study IFN-K-001 on lupus patients: Results of the last group of patients :
Neovacs has presented today the results of the last group of patients enrolled in the phase I/II study with IFNα-Kinoid. These patients have received the 240 mcg dose.
More :
-
28 June 2011 - 10th World Congress on Inflammation-Paris :
Neovacs will today present a poster at the 10th World Congress on Inflammation (
www.inflammation2011.com) ) with the preliminary results of its Phase I/II study of IFNα-Kinoid in lupus.
As announced on the 10th of June 2011, the Scientific Committee nominated it as a “High Graded Poster”, that is to say one of the best in the category, Chemokines and Cytokines.
More :
-
24 June 2011 - Capital Increase by Private Offer :
Neovacs has increased its capital through a private Offer
More :
-
13 June 2011 - Completion of Private Offering :
Neovacs,(Alternext Paris : ALNEV), ), a biotech company focused on an active immunotherapy technology platform (Kinoids) with applications in the treatment of autoimmune diseases, inflammatory diseases and cancer announces the completion of its private placing initiated on June 7th.
More :
-
10 June 2011 - A Neovacs'Poster nominated as "High graded Poster" :
A Neovacs®’ poster selected by the Scientific Committee of the 10th World Congress on Inflammation as one of the best in the Chemokines and Cytokines category
More :
-
09 June 2011 - Neovacs receives €1,448 million from OSEO :
Neovacs receives a payment of €1,448 million from OSEO following achievement of the second key milestone in the Tracker Project with TNF-Kinoid in rheumatoid arthritis.
More :
-
07 June 2011 - Neovacs’ net cash position end April 2011 :
In the context of its private placing, which has been announced June 7th 2011, Neovacs (Alternext Paris : ALNEV), a biotech company focused on an active immunotherapy technology platform (Kinoids) with applications in the treatment of autoimmune diseases, inflammatory diseases and cancer published today its net cash position.
More :
-
06 June 2011 - Neovacs increases its capital via a private placing :
Neovacs launched today a capital increase via a private placing without preemption rights under the provisions of Article L411-2 of the French Financial Code. The placing will be conducted as a book-building exercise and will only be open to qualified investors.
More :
